ARDX vs PHAT
ARDX: Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3 inhibitors. PHAT: Phathom is a commercial-stage biopharmaceutical company commercializing VOQUEZNA, the first US-approved potassium-competitive acid blocker (PCAB) for gastrointestinal diseases including erosive GERD and H. pylori infection.
Side-by-side fundamentals
| Metric | ARDX | PHAT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.08 | $11.70 | |
| Market cap as of 2026-07-23 | $1.3B | $933M | |
| PEG as of 2026-07-23 | -4.33 | n/a | |
| Net margin as of 2026-07-23 | -13.6% | -76.8% | ARDX higher |
| Gross margin as of 2026-07-23 | +92.5% | +84.9% | ARDX higher |
| Operating margin as of 2026-07-23 | -8.8% | -47.5% | ARDX higher |
| ROE as of 2026-07-23 | -38.1% | -232.8% | ARDX higher |
| ROA as of 2026-07-23 | -11.8% | -59.7% | ARDX higher |
| Debt / equity as of 2026-07-23 | 1.37 | 12.38 | ARDX lower |
| Revenue growth (YoY) as of 2026-07-23 | +18.2% | +150.3% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | +98.4% | n/a | |
| Beta as of 2026-07-23 | 0.70 | 0.43 | |
| 1-year return as of 2026-07-22 close | +15.2% | +43.7% | PHAT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.